ReviewStem cell research & therapy2020
Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.
Review in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- When stem cells meet COVID-19: recent advances, challenges and future perspectives.Stem cell research & therapy · 2022Pooled it
- Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Pooled it
- Enhancing immune resilience in swine: a comprehensive meta-review of preventive and host-directed strategies against African swine fever and swine influenza.Frontiers in veterinary science · 2026Review
- Cell therapies for viral diseases: a new frontier.Seminars in immunopathology · 2025Review
- Design, infectability, and transcriptomic analysis of transregionally differentiated and scalable lung organoids derived from adult bronchial cells.bioRxiv : the preprint server for biology · 2024Article
- [Inhibitory effect of 5-hydroxy-6,7-dimethoxyflavone on H1N1 influenza virus-induced ferroptosis and inflammation in A549 cells and its possible mechanisms].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- The Main Mechanisms of Mesenchymal Stem Cell-Based Treatments against COVID-19.Tissue engineering and regenerative medicine · 2024Review
- Genetic modification of miR-34a enhances efficacy of transplanted human dental pulp stem cells after ischemic stroke.Neural regeneration research · 2023Article
- Advancements in Ocular Regenerative Therapies.Biology · 2023Review
- Pulmonary endogenous progenitor stem cell subpopulation: Physiology, pathogenesis, and progress.Journal of intensive medicine · 2023Review
- Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice.Bioengineering (Basel, Switzerland) · 2022Review
- The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury.Acta pharmaceutica Sinica. B · 2022Review
- Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside.Iranian journal of medical sciences · 2022Review
- Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.Stem cell research & therapy · 2022Review
- Athletes' Mesenchymal Stem Cells Could Be the Best Choice for Cell Therapy in Omicron-Infected Patients.Cells · 2022Article
- Down-regulation of microRNA-155 suppressed Candida albicans induced acute lung injury by activating SOCS1 and inhibiting inflammation response.Journal of microbiology (Seoul, Korea) · 2022Article
- Molecular hydrogen is a potential protective agent in the management of acute lung injury.Molecular medicine (Cambridge, Mass.) · 2022Review
- Stem cell therapy for COVID-19 pneumonia.Molecular biomedicine · 2022Review
- MSCs vs. iPSCs: Potential in therapeutic applications.Frontiers in cell and developmental biology · 2022Review
- Phase 1 clinical trial for intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with moderate COVID-19 virus pneumonia: results of stage 1 of the study.American journal of stem cells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Acute lung injury (ALI), an increasingly devastating human disorder, is characterized by a multitude of lung changes arising from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. In particular, influenza virus, coronavirus, and other respiratory viruses circulate in nature in various animal species and can cause severe and rapidly spread human infections. Although scientific advancements have allowed for rapid progress to be made to understand the pathogenesis and develop therapeutics after each viral pandemic, few effective methods to treat virus-induced ALI have been described. Recently, stem cell therapy has been widely used in the treatment of various diseases, including ALI. In this review, we detail the present stem cell-based therapeutics for lung injury caused by influenza virus and the outlook for the future state of stem cell therapy to deal with emerging influenza and coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.